Select immunotherapy agents and ongoing immunotherapy clinical trials in RCC

Ongoing clinical trials for check point inhibitors
 TrialNational clinical trial identifierStatusDisease setting
 Neoadjuvant durvalumab +/− tremelimumabNCT02762006RecruitingNeoadjuvant
 Neoadjuvant pembroNCT02212730RecruitingNeoadjuvant
 Neoadjuvant nivolumabNCT02595918RecruitingNeoadjuvant
 Neoadjuvant nivolumabNCT02575222RecruitingNeoadjuvant
 Nivo vs. nivo + bev vs. nivo + ipiNCT02210117RecruitingNeoadjuvant
 Nivo pre and post-surgeryNCT02446860RecruitingNeoadjuvant/adjuvant
 Phase I pembro + pazopanibNCT02014636RecruitingRefractory
 Phase III nivo vs. everolimusNCT01668784Stopped early and reported in 2015Refractory
 Nivo + sunitinib or pazopanib or ipiNCT01472081Active, not recruitingRefractory
 Pembro + RTNCT02318771RecruitingRefractory
 Phase Ib/II pembro + len in solid tumorsNCT02501096Recruiting solid tumors including RCCRefractory
Ongoing IL-2 based clinical trials
 TrialNational clinical trial identifierStatus
 HD IL-2 + HQNCT01550367Recruiting
 IL-2 +/− SBRTNCT02306954Recruiting
 IL-2 +/− RTNCT01896271Recruiting
 PROCLAIMNCT01415167Registry of HD IL-2 patients
 IL2 + entinostatNCT01038778Ongoing, presented 2016

Abbreviations: Ipi ipilimumab, nivo nivolumab, atezo atezolimumab, bev bevacizumab, pembro pembrolizumab, len lenvatinib, HQ hydroxychloroquine, SBRT stereotactic body radiation therapy, RT radiation therapy